Last reviewed · How we verify
NCT04338958: RuxCoFlam
Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation
Completed
Phase 2
Last updated 13 August 2021
What this trial tests
Phase 2 trial testing Ruxolitinib in Covid-19 in 193 participants. Completed in 15 July 2021.
Timeline
22 April 2020
Primary endpoint
15 July 2021
15 July 2021
15 July 2021
Quick facts
| Lead sponsor | University of Jena |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 193 |
| Start date | 22 April 2020 |
| Primary completion | 15 July 2021 |
| Estimated completion | 15 July 2021 |
| Sites | 6 locations across Germany |
Drugs / interventions tested
- Ruxolitinib (RUXOLITINIB) — full drug profile →
Conditions studied
- Covid-19 — all drugs for Covid-19 →
Sponsor
University of Jena
Who can join
18 and older, any sex, with Covid-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RuxCoFlam is a single arm, non-randomized open phase II trial for front line treatment of Covid-19 patients with defined hyperinflammation.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19.
Bonaventura A, Vecchié A, Dagna L, Martinod K, et al · · 2021 · cited 738× · PMID 33824483 · DOI 10.1038/s41577-021-00536-9 -
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.
Jamilloux Y, Henry T, Belot A, Viel S, et al · · 2020 · cited 486× · PMID 32376392 · DOI 10.1016/j.autrev.2020.102567 -
Drug repurposing approach to fight COVID-19.
Singh TU, Parida S, Lingaraju MC, Kesavan M, et al · · 2020 · cited 299× · PMID 32889701 · DOI 10.1007/s43440-020-00155-6 -
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.
Luo W, Li YX, Jiang LJ, Chen Q, et al · · 2020 · cited 217× · PMID 32580895 · DOI 10.1016/j.tips.2020.06.007 -
COVID-19 and Cancer: a Comprehensive Review.
Gosain R, Abdou Y, Singh A, Rana N, et al · · 2020 · cited 187× · PMID 32385672 · DOI 10.1007/s11912-020-00934-7 -
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794 -
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.
Bikdeli B, Madhavan MV, Gupta A, Jimenez D, et al · · 2020 · cited 180× · PMID 32473596 · DOI 10.1055/s-0040-1713152 -
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
La Rosée F, Bremer HC, Gehrke I, Kehr A, et al · · 2020 · cited 175× · PMID 32518419 · DOI 10.1038/s41375-020-0891-0
Verify or expand the search:
- PubMed search for NCT04338958
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ruxolitinib
Trials testing the same drug.
- NCT07498205 — Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts · Phase 4 · not yet recruiting
- NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
- NCT07311746 — Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07340138 — Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis · Phase 1 · not yet recruiting
- NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting
Other recruiting trials for Covid-19
Currently open trials in the same condition.
- NCT05943743 — Hiccups and Obstacles Of E-Learning Among Medical Sudents · recruiting
- NCT04466683 — Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia · Phase 2 · active not recruiting
- NCT04433364 — COPE - COVID-19 in Pregnancy and Early Childhood · active not recruiting
- NCT04568148 — COVID-19 Biorepository · active not recruiting
- NCT04360538 — Long Term Outcomes of Patients With COVID-19 · active not recruiting
Other University of Jena trials
Trials by the same sponsor.
- NCT07189481 — Design and Evaluation of a Team Timeout Checklist (TTOC) to Improve Information Exchange in the Operating Room Before Sk · completed
- NCT05814874 — Improvement of the Selenium Supply in a Vegan Diet by Different Selenium Sources · NA · completed
- NCT05382533 — MoKaRi II Intervention Study · NA · completed
- NCT05067465 — Nutritional Biomarker Screening for Defined Food Groups · NA · completed
- NCT04902937 — Association of Adjuvant Radiotherapy of Non-metastatic Breast Carcinoma With Immunomodulation and Circulating Tumor Cell · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04338958 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Jena
- Last refreshed: 13 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04338958.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing